This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell therapies, sending the drug developer’s shares down…
Reuters Health Information